Mr Mrs Miss Ms Dr Other

Dr
Frédéric
Didelon

Partner & Patent Attorney

Basel Office Paris Office Bern Office

Life sciences

Email. fdidelon@hgf.com
Vcard
Linkedin

Experience

Frédéric Didelon is a Partner and European Patent Attorney in HGF’s Life Sciences team. He has more than 25 years of IP experience across the pharmaceutical industry, private practice and the European Patent Office, including 17 years at Novartis, where he most recently served as Senior Patent Attorney for R&D IP and Neuroscience.

His background as an EPO examiner, private practice attorney and senior in-house patent counsel gives him a distinctive perspective on patent prosecution, opposition proceedings and strategic IP advisory work. He advises pharmaceutical and biotechnology companies on IP strategies that support research, development, partnering and product lifecycle objectives.

Frédéric has shaped and executed patent strategies for neurodegenerative disease programmes from early research to Phase I–III clinical development, as well as gene therapy projects for rare diseases. His experience spans biologics, gene therapies, neuroscience, rare diseases and small-molecule therapeutics. He has drafted and prosecuted patent applications covering products, medical uses, clinical features, formulations and processes; led IP strategies and advice for global and local project teams, managed global portfolios; conducted numerous IP due diligence; and supported licensing, collaboration and partnering activities. This involved working closely with scientists, clinicians, regulatory experts, business development teams and senior executives to support investment, partnering and lifecycle management decisions.

With a PhD in Biophysics specializing in molecular genetics and neuroscience, Frédéric combines scientific depth, first-hand EPO insight and extensive industry experience to help clients build and defend valuable patent portfolios, navigate complex development and partnering environments, and shape IP strategies that support long-term commercial success.

Specialisms

Industries

Services

Qualifications

Patent Attorney

Europe

Zugelassener Vertreter vor dem Europäischen Patentamt

BSC

DEUG B, Poitiers University, France -1991

DIPL.-ING

Ecole Supérieure de Biotechnologie (ESBS); Strasbourg, France, 1994

MBIOCHEM

DEA Cellular & Molecular Biology, Strasbourg University, France -1994

PHD

Ph.D. in Neuroscience/Biophysics - International School of Advanced Studies (SISSA/ISAS) , Trieste, Italy 1995-1999

Publications

HGF to attend Festival of Biologics 2026

View publication online

CSR

I mentored a Trainee patent attorney at Novartis.

Related News

Event - 27th October 2026

HGF sponsors pro-manchester Retail Lunch 2026

HGF is delighted to be sponsoring pro-manchester Retail Lunch 2026, taking place on Tuesday 27 October 2026 at INNSiDE by Meliá in Manchester. As part of the event, HGF Partner …

Event details
HGF

Office Closed Dates December 2025 / January 2026

HGF Office Closed Dates December 2025 / January 2026   UK Thursday 25 and Friday 26 December 2025 CLOSED Thursday 1 January 2026* CLOSED * Friday 2 January 2026 – …

Read article
HGF

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article
Event - 12th November 2026

HGF Partners with PPTI for 'Designing Foods for Healthy Aging' Webinar

As healthy aging, metabolic health and weight management rise up the consumer agenda, food and nutrition businesses are increasingly looking beyond traditional product development and towards solutions that deliver measurable …

Event details
Event - 15th December 2026

Basel Seminar: Seminar on the new EU Pharma Package and its implications for regulatory exclusivities in the EU

Venue – Der Teufelhof Basel, Switzerland We are pleased to invite you to our seminar on the new EU Pharma Package and its implications for regulatory exclusivities in the EU. …

Event details
Event - 28th October 2026

HGF Attending BMCS Antibody–Drug Conjugates 2026

HGF is pleased to announce that Dr Thomas Lonsdale, Patent Director, will be attending the BMCS Antibody–Drug Conjugates 2026 meeting, taking place on 19 November 2026 at GSK, Stevenage, UK. …

Event details

Hsu Min Chung Recognised in IAM Global Leaders 2027

HGF is delighted to announce that Partner, Hsu Min Chung, has been recognised in the IAM Global Leaders 2027 guide, a prestigious ranking that highlights some of the world’s leading …

Read article
See all updates

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.

Contact us